Pancreatic cancer cells can induce MDSCs that promote tumor cell survival and accumulation [143]C Open in a separate window thead th align=”left” rowspan=”1″ colspan=”1″ /th th align=”left” rowspan=”1″ colspan=”1″ EMT /th th align=”left” rowspan=”1″ colspan=”1″ Angiogenesis /th th align=”left” rowspan=”1″ colspan=”1″ Immunosuppression /th /thead PSCs1. of this article (doi:10.1186/s12935-017-0437-3) contains supplementary material, which is available to authorized users. strong class=”kwd-title” Keywords: Pancreatic malignancy, Tumor microenvironment, Chemotherapy, Myeloid derived suppressor cells, Tumor associated macrophages, Pancreatic stellate cells, Malignancy associated fibroblasts Background Pancreatic malignancy is always referred to pancreatic ductal adenocarcinoma (PDAC) which is the fourth leading malignancy death in USA. Its recent 5-year overall survival of pancreatic malignancy is only 7.7% and its median survival time is about 6?months [1]. Chemotherapy is one of the most important treatments for patients with advanced pancreatic malignancy. Several clinical improvements of chemotherapy have been achieved by high quality, large scale, prospective and randomized clinical Cisplatin trials. Adjuvant chemotherapy based on gemcitabine or fluorouracil have shown encouraging effects to improve the overall survival [2, 3]; oral fluorouracil, S-1, has been reported to show better results than Cisplatin gemcitabine [4]; palliative FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) regimen was reported to be the best choice for patients with metastatic pancreatic cancer [5]. For some selected borderline or local unresectable pancreatic cancer, neoadjuvant chemotherapy have also been initially adopted, with the hope to lower down the tumor and regain the radical resection opportunities [6, 7]. Increasing interests have been put into approaches targeting the tumor stroma of pancreatic cancer. The TME of pancreatic cancer is characterized by dense desmoplasia and extensive immunosuppression [8]. Pancreatic stellate cells (PSCs) and cancer associated fibroblasts (CAFs) are the main matrix-producing cells in TME of pancreatic cancer [9]. Tumor associated macrophages (TAMs) and myeloid derived suppressor cells (MDSCs) are the most infiltration populations of immunosuppressive cells in the TME [10]. The network consisting of stromal cells and cancer cells has become to be the most shining star in the research field of pancreatic cancer. Targeting the stromal components has also shown primary positive results in pancreatic cancer [11C14]. Interactions between chemotherapy and TME have also been paid more and more attentions. On one hand, chemotherapy can induce immunogenic cell death (ICD) in certain tumors, which could potentially activate immune system. On the other hand, these chemotherapeutic drugs can also remodel the TME. Gemcitabine was reported to inhibit the expansion of MDSCs [15], however, it was also reported to induce T helper 2 (Th2) cytokine environment in TME which induce the polarization of M2 polarized TAMs [16]. After gemcitabine treatment, pancreatic cancer secreted more GM-CSF, recruiting MDSCs to diminish the efficacy [17]. Cisplatin or carboplatin increased the potency of tumor cell lines to secrete interleukin (IL)-6 and prostaglandin E2 (PGE2) to induce IL-10-producing M2 polarized TAMs [18]. Four aspects focusing on the chemotherapy and TME of pancreatic cancer were reviewed in this paper, including: clinical landmark advances of chemotherapy in pancreatic cancer, since 2000; interactions and mechanisms between the stromal cells and pancreatic cancer cells; remodeling effects and mechanisms of chemotherapy on TME; targeting of the Cisplatin stromal components in pancreatic cancer. The advances of chemotherapy in pancreatic cancer, since 2000 In respect of adjuvant chemotherapy, in 2001 and 2004, two papers substantially demonstrated that fluorouracil based adjuvant treatment improved overall survival, however chemoradiotherapy showed no survival benefits [2, 19]. In 2007, Oettle et al. [20] reported postoperative gemcitabine improved the estimated disease free survival at 3 and 5?years. In 2010 2010, Neoptolemos et al. reported adjuvant use of fluorouracil plus folinic acid Rabbit Polyclonal to ACSA had comparable results with gemcitabine [3]. In 2013, adjuvant use of gemcitabine was reported to improve the 5-year overall survival and 10-year overall survival [21]. In 2016, Uesaka et al. revealed that Cisplatin adjuvant use of oral fluorouracil (S-1) achieved 44.1% of 5-year overall survival. Recently,.